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Abstract
Introduction: Fetuin-A, a systemic calcification inhibitor, 
has been negatively related to vascular calcification 
(VC) and cardiovascular mortality. In this study we 
investigated the association between fetuin-A levels and 
atherosclerotic vascular complications in systemic lupus 
erythematosus (SLE) patients with and without lupus 
nephritis (LN). 
Methods: We recruited 20 SLE patients without LN, 
20 SLE patients with LN and 20 healthy controls. We 
determined serum creatinine, lipid profile, high sensitivity 
C-reactive protein (hsCRP), calcium, phosphate and 
fetuin-A levels, and calculated the calcification risk 
index (CRI) and SLE disease activity index (SLEDAI) 
for all subjects. Vascular disease burden was assessed by 
quantification of carotid artery intima-media-thickness 
(IMT) and the ankle-brachial index (ABI). 
Results: Fetuin-A levels were significantly lower in 
LN patients (0.47 ± 0.1 g/L) compared to SLE patients 
without LN (0.54 ± 0.1 g/L) and both were significantly 
lower than controls (0.78 ± 0.2 g/L). CRI was significantly 
higher in LN patients (89.1 ± 12.1 mg/L) compared to 
SLE patients without LN (67.2 ± 9.3 mg/L) and both 
were significantly higher than controls (34.2 ± 6.2 mg/L). 
Peripheral arterial disease (ABI < 0.9) was significantly 
more common in LN patients (55%) compared to SLE 
patients without LN (30%) as well as controls (0%). 
Fetuin-A levels showed significant negative correlations 
with serum creatinine, hsCRP, CRI, IMT and ABI in SLE 
patients with and without LN.
Conclusion: Fetuin-A levels were decreased in SLE 
patients with and without LN and negatively correlated 
with vascular complications. This suggests a potentially 
important role for fetuin-A deficiency as marker of 
vascular disease in SLE patients with and without LN. 
Keywords: Atherosclerosis; Fetuin-A; Lupus nephritis; 
SLE; Vascular Calcification.
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Introduction
Systemic lupus erythematosus (SLE) is a multisystem 
autoimmune disease characterized by the production 
of autoantibodies, which can affect all organ systems, 
especially the kidneys. Premature and accelerated 
atherosclerosis is increasingly recognized as being 
prevalent in young female patients with SLE. 
Cardiovascular disease (CVD) develops in 6-9% of 
SLE patients and accounts for up to 36.4% of deaths 
in SLE [1]. Moreover, lupus nephritis (LN) patients 
develop chronic kidney disease (CKD) and experience 
cardiovascular disease risk that is much higher than that 
in age- and sex-matched populations with normal kidney 
function [2]. Several epidemiological studies have 
demonstrated accelerated vascular calcification in CKD 
[3, 4]. Pathological studies have shown that persons with 
end stage renal disease (ESRD) experience accelerated 
atherosclerosis, and also high rates of vascular medial 
calcification [5]. 
Although traditional cardiovascular risk factors apply, 
lupus-associated activation of the immune system 
contributes to the accumulation of vascular damage 
[6]. Defining the autoimmune mechanisms underlying 
these vascular complications is essential to optimize risk 
reduction and develop targeted therapy for prevention of 
CVD in SLE patients. Vascular calcification (VC) in SLE 
may be the main pathogenic factor underling CVD with 
its associated morbidity. In fact, vascular disease can 
practically be used as a diagnostic parameter to evaluate 
the severity of SLE [7]. Measurement of coronary 
calcification may even help detect asymptomatic lupus 
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in patients. Such patients might benefit from aggressive 
interceptive measures, should their condition be detected 
early. Additionally, vascular calcification has far more 
reaching and diverse effects in SLE; which reflects the 
wider diversity of effects produced by vascular disease 
when it is associated with SLE than it does in other 
circumstances [8]. 
Vascular calcification (VC) was previously thought to 
be a passive process aggravated by hyperphosphatemia 
and hypercalcemia that could be controlled adequately 
with careful attention to mineral balance [9]. However, 
accumulating evidence suggests that VC is a regulated 
process affected by intra- and extra-cellular mechanisms 
as well as serum-based proteins [10]. Because human 
serum is supersaturated with respect to calcium and 
phosphorus, the existence of serum-based precipitation 
inhibitors has long been postulated. Human fetuin-A 
(alpha-2-Heremans Schmid glycoprotein), a protein 
produced by the liver and secreted into serum in high 
concentrations, is a major serum-based inhibitor of 
VC and accounts for roughly 50% of the inhibition of 
calcium and phosphorous precipitation [11]. Several 
studies have linked low fetuin-A levels to VCs and flow-
limiting aortic stenosis [12]. Also, fetuin-A has been 
negatively related to VCs and cardiovascular mortality in 
dialysis patients [13]. However, there are only scarce and 
contradictory data on fetuin-A levels in moderate CKD 
and their effect on vessel health. Also, it is still unsolved 
whether in patients with kidney disease the basic biology 
underlying CVD is similar to that acknowledged for 
patients without kidney disease. Many other risk factors 
are present as a consequence of the renal dysfunction and 
thus involved in the accelerated atherosclerotic process 
[14]. The situation is even more complex in patients 
with SLE, who generally suffer from advanced systemic 
atherosclerosis. 
To clarify the relation between fetuin-A and vascular 
complications in SLE patients with and without lupus 
nephritis, we studied the correlation between fetuin-A 
levels and parameters of kidney function, SLE disease 
activity, and vascular disease in SLE patients with and 
without LN.
Methods
Forty SLE patients and twenty controls were randomly 
recruited from persons attending the internal medicine 
department of Kasr El-Aini teaching hospital, Cairo, 
Egypt. The study protocol was approved by the institutional 
ethics committee in Kasr El-Aini teaching hospital, Cairo 
University, and all participants signed a written informed 
consent. Patients and controls were subjected to full 
medical history taking and thorough clinical examination. 
SLE patients fulfilled the diagnostic criteria of the 
American College of Rheumatology (revised in 1982 and 
updated in 1997) [15]. They were all females, their ages 
ranged from 18-41 years, with a mean age of 27.3±6.1 
years. Exclusion criteria included dialysis dependency, 
serum creatinine > 6 mg/dl, coagulation disturbances, 
cancer, diabetes, current intake of oral contraceptives or 
hormone replacement therapy, the presence of any critical 
illness within the last 6 months and specific treatment 
with calcium supplements, phosphate binders, or vitamin 
D. The SLE disease activity was assessed at the time 
of enrollment in the study using the Systemic Lupus 
Erythematosus Disease Activity Index (SLEDAI) score. 
The use of corticosteroid therapy was quantified in terms 
of the average daily dose over the preceding five years 
of the study. SLE patients were divided into two groups 
according to the presence or absence of LN. Patients with 
LN included also those who had documented proteinuria 
associated with hematuria or renal casts in at least two 
separate urine samples in addition to patients with overt 
CKD. The control group included twenty healthy females 
whose age ranged from 19-43 years, with a mean age of 
29.2±5.4 years. All controls had no clinical evidence of 
cardiovascular disease, no evidence of SLE, nephropathy, 
or any immunological disturbances. 
Urine and blood samples were collected from all subjects 
for analysis. Blood was collected after an overnight fast 
(12 h) from the cubital vein. Serum samples were used 
to determine the levels of blood urea nitrogen (BUN), 
serum creatinine, ANA, anti-dsDNA, triglycerides, total 
cholesterol and HDL cholesterol. LDL cholesterol levels 
were calculated by using the Friedewald formula [16]. 
High sensitivity C-reactive protein (hsCRP) was measured 
using the Roche Integra assay [17]. Complement C3 was 
assayed by Assay Max Human C3 complement ELISA 
kit (EC2101-1) [18]. Serum calcium was adjusted for 
serum albumin according to the equation [19]: 
Adjusted calcium (mg/dl) = measured calcium (mg/ dl) + 
[(4.0–serum albumin in g/dl) ×0.8] 
Inorganic phosphate level was measured by 
CHRONOLAB phosphomolybdate UV kit (101- 0458) 
[20]. Fetuin-A was measured in duplicates by an ELISA 
(Epitope Diagnostics, Inc., San Diego, USA) according 
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to the manufacturer’s protocol. The intra- and inter- assay 
variations were 5.3 and 7.1%, respectively [21]. 
The collected data were further used to calculate the 
‘Systemic Lupus Erythematosus Disease Activity Index’ 
(SLEDAI) [23] and the ‘Calcification Risk Index’ (CRI) 
[22]. CRI was calculated by the formula: 
CRI = Calcium level × inorganic phosphate level / 
Fetuin-A  
For manifestations of atherosclerosis, we defined the 
intima-media thickness (IMT) of carotid arteries and 
calculated the ankle-brachial index (ABI). The IMT, were 
detected by carotid ultrasonography using high-resolution 
B-mode ultrasound (Voluson 730 Kretz, Tiefenbach, 
Austria) of the extracranial carotid arteries, bilaterally 
[24].  The whole imaging and quantification procedure was 
performed digitally at the time of study entry by a single 
investigator blinded for clinical data. The measurements 
of IMTs were performed at four points of both common 
carotid arteries ~10 mm proximal to the carotid bulb, 
avoiding areas of atherosclerotic plaque formation. The 
mean of the resulting eight single measurements was 
taken as mean IMT for statistical analyses in this study. 
The ABI was detected by simultaneous measurement of 
the brachial and posterior tibial artery systolic pressure 
[25], using the 5 MHz Mini Dopplex® doppler device 
(Huntleigh Diagnostic Products, Cardiff, UK). Pressure 
was taken at the posterior tibial artery only and the ratio 
of ABI from both sides was taken for analyses. Patients 
were further classified to have prevalent peripheral arterial 
disease (PAD) (ABI < 0.9), no PAD (ABI 0.9-1.3), or 
mediasclerosis (ABI > 1.3).
All data were expressed as mean ± SD. Statistical analyses 
were performed using the SPSS® 15.0 software package 
(SAS Institute Inc., NC, USA). Analysis of variance was 
used to estimate the difference between means. Student-t 
test was used to compare two independent means, and 
Chi-square test was used to compare categorical variables. 
The correlation between clinical and biochemical 
parameters was calculated using Pearson’s correlation 
coefficient. P value < 0.05 was considered statistically 
significant. 
Results
The clinical and laboratory characteristics of patient 
groups and control subjects are summarized in Table-1. 
There were no significant differences between groups 
regarding their age, sex, body mass index (BMI), or 
disease duration. LN patients showed significantly higher 
SLEDAI score, BUN, serum creatinine and blood pressure 
readings compared with SLE patients without nephritis. 
All patients used steroids treatment during the course 
of their disease. Other immunosuppressive treatments 
were used in 11 patients with LN (azathioprine in 5, and 
cyclophosphamide in 2 patients) and hydroxychloroquine 
in 4 patients. 
The blood levels of calcium and inorganic phosphate 
were significantly higher in SLE patients compared 
with healthy control subjects. LN patients showed 
significantly more elevations of phosphate level 
compared with SLE patients without nephritis. Fetuin-A 
levels were significantly lower in SLE patients with and 
without nephritis compared with healthy controls and 
this reduction in fetuin-A level was significantly more 
marked in LN patients compared with SLE patients 
without nephritis. The Calcification Risk Index (CRI) 
was significantly higher in SLE patients compared 
to healthy controls and more marked elevations were 
found in LN patients. We found significantly increased 
IMT in SLE patients compared with healthy controls 
but no significant difference between SLE patients with 
and without LN. Peripheral arterial disease (PAD) was 
detected in significantly more patients with LN than SLE 
patients without nephritis (30% vs. 55%; P < 0.001), 
while no PAD were found in any of the control subjects. 
Only one case of mediasclerosis (ABI > 1.3) was detected 
in the group of LN patients. 
Correlation studies and their significance levels are 
presented in Table-2. Significant negative correlations 
were observed between fetuin-A levels and serum 
creatinine, SLEDAI, hsCRP, CRI, IMT and ABI in 
SLE patients with and without LN. The IMT showed 
significant positive correlations with CRI and hsCRP in 
SLE patients with and without lupus nephritis. The ABI 
showed significant positive correlations with CRI in SLE 
patients with and without LN. 
Discussion
Among persons with ESRD, vascular calcification has 
emerged as a powerful and potentially modifiable risk factor 
of all-cause mortality [26]. Mortality from atherosclerosis 
may be up to 10 times greater in patients with SLE than 
in age- and sex-matched controls [6]. Fetuin-A, a potent 
systemic inhibitor of soft tissue calcification, has been 
negatively related to VCs and cardiovascular mortality in 
dialysis patients [13]. Serum concentrations of fetuin-A 
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are depressed in patients with ESRD, and lower serum 
concentrations were independently associated with risk of 
cardiovascular and all-cause mortality in this population 
[27]. Also, serum fetuin-A levels were found to be lower 
in SLE patients and its level correlates with disease 
activity [22]. Whether serum fetuin-A concentrations are 
associated with kidney function, and whether the protein 
acts as a key calcification inhibitor in mild-to-moderate 
CKD such as LN, is unknown. Yet, associations of novel 
biomarkers such as fetuin-A with metabolic markers or 
complications do help in understanding their role in the 
pathophysiology of vascular disease.
Current results showed that LN patients have significantly 
higher blood pressure, serum creatinine, BUN and 
SLEDAI score, which are expected to be associated with 
active kidney affection. SLE patients with or without LN 
showed significantly high levels of TG, total cholesterol, 
LDL, but low levels of HDL, as compared to healthy 
controls. These results are in accordance with those 
reported by Thomas et al [1], stating that SLE patients 
exhibit an atherogenic lipid profile characterized by 
elevated TG and VLDL, with reduced HDL. This form 
of dyslipidemia is attributed to the interplay between 
multiple disease parameters. For instance, elevated levels 
SLE without LN LN Controls 
Clinical data (n = 20) (n = 20) (n = 20)
Age (years) 25.6 ± 4.1 28.3 ± 4.6 29.2 ± 5.4
BMI (kg/m2) 26.9 ± 5.4 31.2 ± 7.5 28.1 ± 4.5
Systolic blood pressure (mmHg) 127 ± 24 154 ± 37*$ 122 ± 21
Diastolic blood pressure (mmHg) 76 ± 18 98 ± 21*$ 73 ± 15
Duration of SLE disease (years)     5.2 ± 1.5 5.9 ± 1.8 -
Drugs used:     Current steroids 16/20 13/20 -
                         Former steroids 4/20 7/20 -
                         Immunosuppressives - 11/20 -
SLE Disease Activity Index (SLEDAI) 23.6±5.7 28.9±7.1$  -
Blood Urea Nitrogen (mg/dL) 37.2±11.4 183.5±34.1*$ 25.1±6.1
Serum Creatinine (mg/dL) 1.2±0.3 3.9±1.1*$ 0.8±0.2
hsCRP (mg/L) 2.4±0.6* 4.1±0.8*$ 1.3±0.4
C3 Complement Level (g/L) 81.4±21.5* 75.8±16.9* 129.4±28.0
Triglycerides (mg/dL) 162.6±24.1* 171.5±29.3* 134.6±18.7
Total Cholesterol (mg/dL) 184.4±36.9* 198.5±31.2* 155.3±27.6
HDL–Cholesterol (mg/dL) 33.2±8.1* 31.2±7.4* 42.7±8.9
LDL–Cholesterol (mg/dL) 108.5±21.5* 117.4±26.8* 93.6±19.3
Calcium (mg/dL) 9.8±1.4* 9.3±1.3* 8.6±1.1
Inorganic Phosphate (mg/dL) 3.7±0.7* 4.5±0.9*$ 3.1±0.6
Calcification Risk Index (CRI) 67.2±9.3* 89.1±12.1*$ 34.2±6.2
Fetuin–A (g/L) 0.54±0.1* 0.47±0.1*$ 0.78±0.2
Intima–Media Thickness (IMT, mm) 0.6±0.3* 0.8±0.3* 0.3±0.1
Peripheral Arterial Disease (ABI < 0.9) 6/20 (30%)* 11/20 (55%)*$ 0/20 (0%)
Table-1: Clinical data, diagnostic indices, and blood biochemical analysis for SLE patients without LN, with LN and healthy 
controls. 
Values are presented as mean ± SD or proportions. 
* significant change as compared to healthy controls. 
$ significant change as compared to SLE patients without nephritis. 
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of interleukin–1 and interferons have been reported 
to suppress lipoprotein lipase activity [28], and in turn 
reduce the catabolism of TG-rich VLDL and subsequent 
formation of LDL. Steroid therapy further elevates TG 
levels; possibly through a similar effect on lipoprotein 
lipase activity or by promoting insulin resistance [29]. 
These disturbances, alongside the pro-inflammatory, pro-
oxidative state shown to exist in SLE, add up to enhance 
the atherogenic propensity in SLE. 
In addition to the atherogenic lipid profile, autoantibodies 
are also thought to play a major role in SLE-related 
atherogenesis, especially those directed against 
apolipoprotein H and against the endothelium [30]. 
The latter are of particular interest clinically because of 
their direct, relation to endothelial apoptosis observed in 
SLE [31]. The immune complexes deposited in vascular 
walls at sites of vascular injury activate the complement 
pathway which, in turn, evokes further inflammatory and 
autoimmune responses that accelerate atherogenesis and 
vascular calcification [32]. The levels of hsCRP were 
significantly higher in SLE patients, and the increase was 
significantly more marked in patients with LN, reflecting 
the active inflammatory condition. Complement C3 
levels were significantly lower in all SLE patients with 
and without LN, compared with the control group. These 
results are in line with the observations by Grevink et 
al [33], stating that complement factors facilitate the 
clearance of apoptotic cells and, when decreased, might 
result in an increased amount of apoptotic cells, such as 
those found in SLE patients. In fact, low levels of one or 
more complement factors, due to increased catabolism, 
are found in the majority of patients with SLE.
In our study, calcium and inorganic phosphate levels 
were significantly higher in SLE patients compared with 
healthy controls. LN patients showed less elevation of 
calcium, but more elevation of phosphate levels compared 
to SLE patients without nephritis. Fetuin-A levels were 
significantly lower and calcification risk index (CRI) 
was higher in SLE patients, and these changes were 
more marked in patients with LN. Mehrotra et al [27] 
     SLE without LN         SLE with LN
R P R P
Fetuin–A (g/l)
      Serum creatinine (mg/dL) – 0.68   < 0.001 – 0.74   < 0.001 
      SLE Disease Activity Index (SLEDAI) – 0.49   < 0.01 – 0.61   < 0.01 
      hsCRP (mg/dL) – 0.47   < 0.01 – 0.35   < 0.05 
      Calcification Risk Index (CRI) – 0.83   < 0.001 – 0.88   < 0.001 
      Intima–Media Thickness (IMT, mm) – 0.57   < 0.01 – 0.70   < 0.001 
      Ankle–Brachial index (ABI)  – 0.62   < 0.001 – 0.59   < 0.01 
Intima-Media Thickness (IMT, mm)
      Serum creatinine (mg/dL) 0.17   > 0.05 0.38   < 0.05 
      SLE Disease Activity Index (SLEDAI) 0.36   < 0.05 0.26   > 0.05 
      hsCRP (mg/dL) 0.47   < 0.05 0.63   < 0.01 
      Calcification Risk Index (CRI) 0.52   < 0.01 0.58   < 0.01 
      Ankle–Brachial index (ABI)  0.25   > 0.05 0.09   > 0.05 
Ankle-Brachial index (ABI) 
      Serum creatinine (mg/dL) 0.30   > 0.05 0.54   < 0.01 
      SLE Disease Activity Index (SLEDAI) 0.21   > 0.05 0.16   > 0.05 
      hsCRP (mg/dL) 0.06   > 0.05 0.15   > 0.05
      Calcification Risk Index (CRI) 0.78   < 0.001 0.69   < 0.001 
Table-2: Correlation coefficients and significance levels among clinical indexes and blood biochemical parameters in SLE 
patients with and without LN. 
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observed higher serum concentrations of fetuin-A among 
patients with advanced diabetic nephropathy (CKD 
stages 1 to 4) as compared with persons with diabetes 
but without kidney disease. Osawa and colleagues 
[34] reported no association between serum fetuin-A 
concentrations and total and albumin-corrected calcium, 
and an inverse correlation with serum phosphorous 
concentrations among healthy Japanese volunteers 
without kidney disease. In an unadjusted analysis, Ix et 
al [12] found that higher serum fetuin-A concentrations 
were associated with higher serum calcium and 
phosphorous concentrations, independent of kidney 
function. Fetuin-A, a binder/carrier of serum calcium–
phosphate, stabilizes the concentration of serum calcium 
and prevents its precipitation. It promotes phagocytosis 
of redundant calcium and thus, it is regarded as a potent 
circulating inhibitor of cardiovascular calcification [35]. 
The present study showed the existence of significant 
correlations between low fetuin-A levels and serum 
creatinine, SLEDAI, CRI, IMT and ABI in SLE patients, 
with and without nephritis. Low serum fetuin-A levels 
were previously observed in SLE patients and were 
found to correlate with SLEDAI and IMT [22]. Mori et 
al [36] reported that feutin-A levels are related to carotid 
arterial stiffness, regardless of the nature of contributing 
atherogenic factors.
In young population with mild-to-moderate alterations in 
renal function and with less traditional cardiovascular risk 
factors, Kanbay et al [14] observed small modifications 
in serum levels of fetuin-A early in the course of disease 
evolution that can predict the extent of coronary artery 
disease. Ketteler et al [21] demonstrated that lower 
fetuin-A concentrations were independently associated 
with cardiovascular and all-cause mortality in dialysis 
patients. These results were recently confirmed in incident 
hemodialysis and peritoneal dialysis patients [37]. As 
fetuin-A is a potent inhibitor of vascular calcification 
and as low levels had been associated with coronary 
artery and valvular calcification [38], the hypothesis was 
generated that the excess mortality risk observed in these 
studies may have been due to accelerated cardiovascular 
calcification among ESRD patients with lower serum 
concentrations of fetuin-A. Our results indicated 
significantly increased IMT of carotid arteies in SLE 
patients and this was more marked in LN patients. The 
IMT had significant positive correlations with CRI and 
hsCRP, but significant negative correlations with fetuin-A 
levels. These observations seem to fall in accordance 
with the findings of other investigators who pointed to 
non–traditional risk factors as the most probable reason 
behind the high prevalence of atherosclerosis in SLE 
patients [39]. However, recent studies showed a strong 
association between fetuin-A levels and events of CVD. 
Weikert et al [40] obtained a significantly increased 
risk for myocardial infarction and ischemic stroke for 
individuals in the highest compared with the lowest 
quintile of fetuin-A in a model adjusted for cardiovascular 
risk factors including age, sex, diabetes, BMI, HDL, 
and hsCRP. Also, Fisher et al [41] have suggested that 
fetuin-A and fetuin-A gene polymorphisms may play 
a causal role in the pathophysiology of atherosclerosis 
leading to CV events.  
Contradictory results have also been published regarding 
the role of fetuin-A in macrovascular disease in patients 
with type-2 diabetes. While some studies associated 
lower fetuin-A levels with peripheral arterial disease 
(PAD) [25], others observed an association of increased 
fetuin-A levels with coronary artery calcification [27, 
42]. Estimation of the ankle-brachial index (ABI) in 
this study detected peripheral arterial disease (PAD) in 
significantly more LN patients than SLE patients without 
nephritis. This correlated significantly with CRI, but 
correlated negatively with serum fetuin-A levels. ABI 
also correlated significantly with serum creatinine in 
LN patients. These findings support the hypothesis that 
low fetuin-A might result in vascular calcification. Also, 
Eraso et al [25] found that patients with type-2 diabetes 
and PAD have lower levels of fetuin-A than patients 
with type-2 diabetes alone. However, Lorant et al [42] 
demonstrated that patients with type-2 diabetes who 
additionally suffer from PAD have significantly higher 
fetuin-A levels than patients with diabetes but without any 
atherosclerotic burden. Low fetuin-A was also associated 
with mediasclerosis in patients with diabetes and PAD. 
The role of fetuin-A and its involvement in atherosclerosis 
seems to be very complex and is not yet understood. 
Atherosclerotic plaques, in general, provoke fibrosis 
and vascular calcification, which is a marker of 
increased vulnerability to cardiovascular events and 
mortality. Reduced fetuin-A levels are associated with 
inflammation and increased cardiovascular calcification 
(CVC) [43]. In experimental mice with kidney disease 
that were provided high phosphate feeding, wild-type 
mice developed high serum calcium and phosphorous 
levels, but did not develop extra-osseous calcification. In 
contrast, fetuin-A knockout mice developed significant 
soft tissue calcification while maintaining normal serum 
calcium and phosphorous levels [44]. These findings 
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suggest that under certain conditions, elevated serum 
concentrations of calcium and phosphorus may reflect 
improved ion solubility. The presence of pre-existing 
CVD and alterations in mineral metabolism conferred 
by CKD may have led to the up-regulation of fetuin-A 
in association with elevated calcium and phosphorous 
levels, perhaps to offset the propensity towards dystrophic 
mineralization [12]. Structure–function studies have 
suggested that fetuin-A solubilizes calcium phosphate 
crystals by direct and reversible binding, reminiscent 
of the process in which apolipoproteins solubilize lipids 
in solution [45]. In humans so far the available data has 
been inconsistent. Lower fetuin-A levels are associated 
with mortality and coronary vascular disease events in 
cohorts with ESRD [26], while a population based study 
linked high plasma fetuin-A levels to an increased risk 
of myocardial infarction and ischemic stroke [40]. Yet, 
no association could be detected between fetuin-A, and 
traditional cardiovascular risk factors, cardiovascular 
outcome or the metabolic syndrome in patients with 
manifest CHD in a 6-year follow up study [46]. Our 
results detected an inverse correlation between serum 
fetuin-A levels and hsCRP levels in SLE patients with 
and without LN. However, Hennige et al [47] found a 
positive correlation between circulating fetuin-A and 
hsCRP, a systemic marker of subclinical inflammation. 
Contrariwise to renal dialysis patients, several studies 
showed that high levels of fetuin-A were associated 
with atherosclerosis and its manifestations in non-renal 
patients [40]. This possible involvement of fetuin-A 
in the pathogenesis of cardiovascular disease has been 
confirmed by a recent trans-European cohort study 
with 2,520 patients [41]. Thus, it seems that high levels 
of fetuin-A are associated with atherosclerosis and its 
manifestations in non-renal patients.
Because those studies were cross-sectional, it is not 
impossible that fetuin-A had detrimental effects on the 
vasculature. It is possible that fetuin-A is upregulated 
to protect against calcification but deteriorates 
atherosclerosis [12]. Nevertheless, patients with media 
artery sclerosis showed significantly lower levels of 
fetuin-A. This is in line with the calcification inhibition 
competence of fetuin-A [42]. It is to be noted that, in the 
past few years, many biological parameters in humans 
were shown to follow not a simple linear association, 
but a U-shaped relationship (such as BMI, hemoglobin). 
Ix et al [12] suggested a U-shaped relationship also for 
fetuin-A values with CVD. They considered either high 
or low levels of fetuin-A to predict cardiovascular events. 
High levels by associations with metabolic syndrome 
and atherogenic lipids result in CVD and low levels by 
associations with vascular calcification also result in 
CVD.
A point worthy emphasis in this study is the effect of 
medication on lupus-associated atherosclerosis. All 
patients used steroids treatment during the course of the 
disease; most of them were current users of steroids in a 
dose range of 20 to 60 mg/day. More than half the patients 
with LN used immunosuppressive treatment, in addition 
to steroids. Corticosteroid therapies have been shown 
to have adverse effects on the traditional risk factors 
of atherosclerosis such as blood pressure, lipid profile, 
obesity, and blood glucose level [29]. Although there is 
very little dispute about the beneficial anti–inflammatory 
effect of corticosteroid therapy, there seems to be, a 
disagreement about the criteria defining an ‘adequate’ 
corticosteroid dose. Several investigators suggested 
that, as far as SLE patients are concerned, corticosteroid 
doses are considered sufficient only if they are enough to 
prevent premature atheromatosis [48]. Certain findings in 
this study may add some justification to that approach as 
it was observed, by comparing the patient’s histories, that 
patients with increased IMT always had less prednisone 
medication, in both frequency and dose. 
A relative strength of our study is the availability of 
several parameters of kidney function and measurement 
of multiple potential risk factors for vascular disease. 
However, there are several limitations that should be 
considered when interpreting our results. Our study 
could not evaluate the association of advanced CKD and 
serum fetuin-A. For now, the mechanisms explaining 
the association between CKD and vascular calcification 
remain elusive. Whether a threshold of kidney function 
exists, at which fetuin-A concentrations decline cannot be 
addressed in our study sample. A better understanding of 
the regulation of fetuin-A in the presence and absence of 
uremia and vascular disease and at varying concentrations 
of calcium and phosphorus is required. The cross-sectional 
design of our study does not allow for causal inference or 
evaluation of direction of associations. Finally, our study 
participants were all females and had SLE; and therefore 
results may not be generalizable to men or to persons 
without SLE disease.
Arab Journal of Nephrology and Transplantation
18
Abdel-Wahab, Fathy and Al-Harizy
Conclusion
In conclusion, fetuin-A levels were decreased in SLE 
patients with and without LN and these levels were 
inversely correlated with vascular complications. 
This suggests a potentially important role for fetuin-A 
deficiency as a biomarker of vascular disease in patients 
with SLE and LN. 
References
1. Thomas GN, Tam LS, Tomlinson B, Li EK. 
Accelerated atherosclerosis in patients with systemic 
lupus erythematosus: a review of the causes and possible 
prevention. Hong Kong Med J. 2002 Feb;8(1):26-32.
2.  Foley RN, Parfrey PS, Sarnak MJ. Clinical 
epidemiology of cardiovascular disease in chronic 
renal disease. Am J Kidney Dis. 1998 Nov;32(5 Suppl 
3):S112-9.
3. Chertow GM, Raggi P, Chasan-Taber S, Bommer 
J, Holzer H, Burke SK. Determinants of progressive 
vascular calcification in haemodialysis patients. Nephrol 
Dial Transplant. 2004 Jun;19(6):1489-96.
4.  Kramer H, Toto R, Peshock R, Cooper R, Victor R. 
Association between chronic kidney disease and coronary 
artery calcification: the Dallas Heart Study. J Am Soc 
Nephrol. 2005 Feb;16(2):507-13.
5. Ibels LS, Alfrey AC, Huffer WE, Craswell PW, 
Anderson JT, Weil R 3rd. Arterial calcification and 
pathology in uremic patients undergoing dialysis. Am J 
Med. 1979 May;66(5):790-6.
6.  El-Magadmi M, Ahmad Y, Wajed J and Bruce IN. The 
bimodal mortality pattern in systemic lupus erythematosis. 
Curr Med Lit Rheumatol. 2003;22:1-6. 
7. Urowitz MB, Gladman DD. Atherosclerosis and lupus: 
the SLICC Study. Lupus. 2007;16(12):925-8.
8.  Harley JB, Kelly JA, Kaufman KM. Unraveling the 
genetics of systemic lupus erythematosus. Springer 
Semin Immunopathol. 2006 Oct;28(2):119-30. 
9. Alfrey AC, Ibels LS. Role of phosphate and 
pyrophosphate in soft tissue calcification. Adv Exp Med 
Biol. 1978;103:187-93.
10.  Ketteler M, Westenfeld R, Schlieper G, Brandenburg 
V, Floege J. “Missing” inhibitors of calcification: general 
aspects and implications in renal failure. Pediatr Nephrol. 
2005 Mar;20(3):383-8.
11. Jahnen-Dechent W, Schinke T, Trindl A, Müller-
Esterl W, Sablitzky F, Kaiser S, Blessing M. Cloning and 
targeted deletion of the mouse fetuin gene. J Biol Chem. 
1997 Dec 12;272(50):31496-503.
12.  Ix JH, Chertow GM, Shlipak MG, Brandenburg 
VM, Ketteler M, Whooley MA. Association of fetuin-A 
with mitral annular calcification and aortic stenosis 
among persons with coronary heart disease: data from 
the Heart and Soul Study. Circulation. 2007 May 
15;115(19):2533-9.
13.  Chertow GM, Burke SK, Raggi P; Treat to Goal 
Working Group. Sevelamer attenuates the progression of 
coronary and aortic calcification in hemodialysis patients. 
Kidney Int. 2002 Jul;62(1):245-52.
14. Kanbay M, Nicoleta M, Selcoki Y, Ikizek M, Aydin M, 
Eryonucu B, Duranay M, Akcay A, Armutcu F, Covic A. 
Fibroblast growth factor 23 and fetuin A are independent 
predictors for the coronary artery disease extent in mild 
chronic kidney disease. Clin J Am Soc Nephrol. 2010 
Oct;5(10):1780-6.
15.  Tan EM, Cohen AS, Fries JF, Masi AT, McShane 
DJ, Rothfield NF, Schaller JG, Talal N, Winchester 
RJ. The 1982 revised criteria for the classification of 
systemic lupus erythematosus. Arthritis Rheum. 1982 
Nov;25(11):1271-7.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation 
of the concentration of low-density lipoprotein cholesterol 
in plasma, without use of the preparative ultracentrifuge. 
Clin Chem. 1972 Jun;18(6):499-502.
17.  Beattie MS, Shlipak MG, Liu H, Browner WS, 
Schiller NB, Whooley MA. C-reactive protein and 
ischemia in users and nonusers of beta-blockers and 
statins: data from the Heart and Soul Study. Circulation. 
2003 Jan 21;107(2):245-50.
18. Peakman M, Lobo-Yeo A, Senaldi G, Nilsson M, Tee 
DE, Vergani D. Quantification of C3d in biological fluids 
by an enzyme-linked immunosorbent assay. J Immunol 
Methods. 1987 Nov 23;104(1-2):51-6.
19.  Chen NX, O’Neill KD, Chen X, Duan D, Wang E, 
Sturek MS, Edwards JM, Moe SM. Fetuin-A uptake in 
bovine vascular smooth muscle cells is calcium dependent 
and mediated by annexins. Am J Physiol Renal Physiol. 
2007 Feb;292(2):F599-606.
20.  Burtis CA, Ashwood ER, Bruns DE. Text Book of 
Clinical Chemistry and Molecular Diagnostics. 4th ed. St 
Louis: Elsevier Saunders Company; 2006. p. 837-903. 
21. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, 
Mahnken AH, Böhm R, Metzger T, Wanner C, Jahnen-
Dechent W, Floege J. Association of low fetuin-A 
(AHSG) concentrations in serum with cardiovascular 
Arab Journal of Nephrology and Transplantation
19
Fetuin-A and Vascular Disease in SLE
mortality in patients on dialysis: a cross-sectional study. 
Lancet. 2003 Mar 8;361(9360):827-33.
22.  Khalil ES, Sharaf EA, Abdel-Rehim WM and 
Rashsd MM. Serum level of fetuin-A in systemic lupus 
erythematosis: Relation to disease activity and accelerated 
atherosclerosis. J Biophysics and Biomedical Sciences. 
2008;1(2):92-7. 
23. Bombardier C, Gladman DD, Urowitz MB, Caron D, 
Chang CH. Derivation of the SLEDAI. A disease activity 
index for lupus patients. The Committee on Prognosis 
Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630-
40.
24. Rittig K, Thamer C, Haupt A, Machann J, Peter A, 
Balletshofer B, Fritsche A, Haring HU, Stefan N. High 
plasma fetuin-A is associated with increased carotid 
intima-media thickness in a middle-aged population. 
Atherosclerosis. 2009 Dec;207(2):341-2.
25. Eraso LH, Ginwala N, Qasim AN, Mehta NN, 
Dlugash R, Kapoor S, Schwartz S, Schutta M, Iqbal N, 
Mohler ER 3rd, Reilly MP. Association of lower plasma 
fetuin-a levels with peripheral arterial disease in type 2 
diabetes. Diabetes Care. 2010 Feb;33(2):408-10.
26. Blacher J, Guerin AP, Pannier B, Marchais SJ, 
London GM. Arterial calcifications, arterial stiffness, 
and cardiovascular risk in end-stage renal disease. 
Hypertension. 2001 Oct;38(4):938-42.
27. Mehrotra R, Westenfeld R, Christenson P, Budoff 
M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, 
Adler S. Serum fetuin-A in nondialyzed patients with 
diabetic nephropathy: relationship with coronary artery 
calcification. Kidney Int. 2005 Mar;67(3):1070-7.
28. Fried SK, Appel B, Zechner R. Interleukin 1 alpha 
decreases the synthesis and activity of lipoprotein 
lipase in human adipose tissue.  Horm Metab Res. 1993 
Feb;25(2):129-30.
29. Tchernof A, Labrie F, Bélanger A, Després JP. 
Obesity and metabolic complications: contribution of 
dehydroepiandrosterone and other steroid hormones. J 
Endocrinol. 1996 Sep;150 Suppl:S155-64.
30. Matsuura E, Koike T. Accelerated atheroma 
and anti-beta2-glycoprotein I antibodies.  Lupus. 
2000;9(3):210-6.
31. Rajagopalan S, Somers EC, Brook RD, Kehrer C, 
Pfenninger D, Lewis E, Chakrabarti A, Richardson BC, 
Shelden E, McCune WJ, Kaplan MJ. Endothelial cell 
apoptosis in systemic lupus erythematosus: a common 
pathway for abnormal vascular function and thrombosis 
propensity. Blood. 2004 May 15;103(10):3677-83.
32. Matsuura E, Kobayashi K, Inoue K, Lopez LR, 
Shoenfeld Y. Oxidized LDL/beta2-glycoprotein I 
complexes: new aspects in atherosclerosis. Lupus. 
2005;14(9):736-41.
33. Grevink ME, Horst G, Limburg PC, Kallenberg 
CG, Bijl M. Levels of complement in sera from inactive 
SLE patients, although decreased, do not influence in 
vitro uptake of apoptotic cells. J Autoimmun. 2005 
Jun;24(4):329-36.
34. Osawa M, Tian W, Horiuchi H, Kaneko M, Umetsu 
K. Association of alpha2-HS glycoprotein (AHSG, 
fetuin-A) polymorphism with AHSG and phosphate 
serum levels. Hum Genet. 2005 Feb;116(3):146-51.
35. Kuźniar J, Porazko T, Klinger M. Relationship between 
fetuin-A concentration, elevated levels of inflammatory 
markers, and arterial wall stiffness in end-stage kidney 
disease. J Ren Nutr. 2008 Jan;18(1):83-6.
36. Mori K, Emoto M, Araki T, Yokoyama H, Teramura 
M, Lee E, Motoyama K, Koyama H, Shoji T, Inaba 
M, Nishizawa Y. Association of serum fetuin-A with 
carotid arterial stiffness. Clin Endocrinol (Oxf). 2007 
Feb;66(2):246-50.
37. Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao 
P, Lui SF, Li PK, Sanderson JE. Associations of serum 
fetuin-A with malnutrition, inflammation, atherosclerosis 
and valvular calcification syndrome and outcome in 
peritoneal dialysis patients. Nephrol Dial Transplant. 
2005 Aug;20(8):1676-85.
38. Moe SM, Reslerova M, Ketteler M, O’neill K, Duan 
D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen 
NX. Role of calcification inhibitors in the pathogenesis of 
vascular calcification in chronic kidney disease (CKD). 
Kidney Int. 2005 Jun;67(6):2295-304.
39. Roman MJ, Salmon JE, Sobel R, Lockshin MD, 
Sammaritano L, Schwartz JE, Devereux RB. Prevalence 
and relation to risk factors of carotid atherosclerosis 
and left ventricular hypertrophy in systemic lupus 
erythematosus and antiphospholipid antibody syndrome. 
Am J Cardiol. 2001 Mar 1;87(5):663-6, A11.
40. Weikert C, Stefan N, Schulze MB, Pischon T, Berger 
K, Joost HG, Häring HU, Boeing H, Fritsche A. Plasma 
fetuin-a levels and the risk of myocardial infarction and 
ischemic stroke. Circulation. 2008 Dec 9;118(24):2555-
62.
41. Fisher E, Stefan N, Saar K, Drogan D, Schulze MB, 
Fritsche A, Joost HG, Häring HU, Hubner N, Boeing H, 
Weikert C. Association of AHSG gene polymorphisms 
with fetuin-A plasma levels and cardiovascular diseases 
Arab Journal of Nephrology and Transplantation
20
Abdel-Wahab, Fathy and Al-Harizy
in the EPIC-Potsdam study. Circ Cardiovasc Genet. 2009 
Dec;2(6):607-13.
42. Lorant DP, Grujicic M, Hoebaus C, Brix JM, Hoellerl 
F, Schernthaner G, Koppensteiner R, Schernthaner GH. 
Fetuin-A levels are increased in patients with type 2 
diabetes and peripheral arterial disease. Diabetes Care. 
2011 Jan;34(1):156-61.
43. Schinke T, Amendt C, Trindl A, Pöschke O, Müller-
Esterl W, Jahnen-Dechent W. The serum protein 
alpha2-HS glycoprotein/fetuin inhibits apatite formation 
in vitro and in mineralizing calvaria cells. A possible role 
in mineralization and calcium homeostasis. J Biol Chem. 
1996 Aug 23;271(34):20789-96.
44. Westenfeld R, Smeets R and Schaefer C. The effect 
of fetuin-A, phosphate, and uremia on the induction of 
extraosseous calcification in mice. J Am Soc Nephrol. 
2004;15:270A.
45. Heiss A, DuChesne A, Denecke B, Grötzinger J, 
Yamamoto K, Renné T, Jahnen-Dechent W. Structural basis 
of calcification inhibition by alpha 2-HS glycoprotein/
fetuin-A. Formation of colloidal calciprotein particles. J 
Biol Chem. 2003 Apr 11;278(15):13333-41.
46. Roos M, von Eynatten M, Heemann U, Rothenbacher 
D, Brenner H, Breitling LP. Serum fetuin-A, cardiovascular 
risk factors, and six-year follow-up outcome in patients 
with coronary heart disease. Am J Cardiol. 2010 Jun 
15;105(12):1666-72.
47. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche 
A, Haring HU and Stefan N. Fetuin-A induces cytokine 
expression and suppresses adiponectin production. PLoS 
ONE. 2008 Mar 12;3(3):e1765.
48. Roman MJ, Shanker BA, Davis A, Lockshin MD, 
Sammaritano L, Simantov R, Crow MK, Schwartz JE, 
Paget SA, Devereux RB, Salmon JE. Prevalence and 
correlates of accelerated atherosclerosis in systemic lupus 
erythematosus. N Engl J Med. 2003 Dec 18;349(25):2399-
406.
